Financials
- Financial year
- 2024
- Total assets
- €45,069
- Loss
- -€9,572
- Solvency
- -351.9%
Total assets=
Net result
20182024
VASCULAR RESEARCH NETWORK BVBA
ActiveSummary
The computed 12-month bankruptcy probability of VASCULAR RESEARCH NETWORK BVBA is 2.2% (moderate). The 2024 annual accounts show negative equity (-€158,577) and a net result of -€9,572. Equity is shrinking by about 4.9% per year across the filed financial years. The company has been active since 2014 and the Belgian Official Gazette contains no insolvency or warning signals.
Overview
Activity
“Het verrichten van onderzoek op medisch gebied, in het bijzonder op het gebied van…” (deed in Dutch)
From the articles, 3 activitiesNo NACE code in the KBO yet1 site
Size
€45,069total assets 2024
- Equity
- -€158,577
- Loss
- -€9,572
Turnover not published (abbreviated format)
Structure
- Excelya NetherlandsDirector
2025 accounts not filed, 88 days past the deadline2 of 9 deeds summarised
Why 52raises riskNo main activity registeredFigures for financial year 2024 (filed 02-07-2025)lowers riskSize: total assets €45,069Founded in 2014Show the evidence
Checked score
Score 2024
52
/ 100
Fair
Probability in this band: 1.5% to 4.2%
Financially better than 33% of its sector peers (no NACE code, micro)
Financial strength · tick = 2023
Weak
Solvency
0=
equity -351.9% of total assets
Liquidity
100=
short-term debt 5.8% · cash 89.2%
Profitability
0=
return on assets -21.2%
Bankruptcy probability, 12 months
2.2%
Moderate
0%0.5%1.5%4%10%≥ 25%
About 2 in 100 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
11-2024: 2.2%
12-2024: 2.2%● unchanged vs 11-2024
01-2025: 2.2%● unchanged vs 12-2024
02-2025: 2.2%● unchanged vs 01-2025
03-2025: 2.1%▼ -0.1 percentage points vs 02-2025
04-2025: 2.2%▲ +0.1 percentage points vs 03-2025
05-2025: 2.1%▼ -0.1 percentage points vs 04-2025
06-2025: 2.2%▲ +0.1 percentage points vs 05-2025
07-2025: 2.2%● unchanged vs 06-2025highest value
08-2025: 1.9%▼ -0.3 percentage points vs 07-2025
09-2025: 1.9%● unchanged vs 08-2025
10-2025: 1.4%▼ -0.5 percentage points vs 09-2025
11-2025: 1.4%● unchanged vs 10-2025
12-2025: 1.4%● unchanged vs 11-2025
01-2026: 1.4%● unchanged vs 12-2025
02-2026: 1.3%▼ -0.1 percentage points vs 01-2026
03-2026: 1.3%● unchanged vs 02-2026
04-2026: 1.3%● unchanged vs 03-2026
05-2026: 1.3%● unchanged vs 04-2026
06-2026: 1.3%● unchanged vs 05-2026
07-2026: 1.3%● unchanged vs 06-2026lowest value
08-2026: 1.5%▲ +0.2 percentage points vs 07-2026
09-2026: 1.6%▲ +0.1 percentage points vs 08-2026
10-2026: 2.2%▲ +0.6 percentage points vs 09-2026
No credit on open account
Liquidity ample (current ratio 17.13, compared with 17.13 in 2023, above the usual 1.5; short-term debt: 5.8% and cash: 89.2% of total assets), but equity is negative.
How it is calculated
The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (no NACE code, micro): better than 5% on solvency, 95% on liquidity, 4% on profitability and 29% on growth.
The bankruptcy probability was computed on 26-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).
Credit check for your own amount and term
Show the recommended maximum and see how the verdict changes with amount, term and advance.
Signals
Seven signals.
lowers riskraises riskneutral
raises risk · Negative equity
The 2024 annual accounts show negative equity and a net loss.
NBB · annual accounts 2024Equity per financial year
18192021222324
2018 to 2024 · latest year -€158,577
raises risk · Annual accounts not filed
The financial year that closed on 31-12-2025 was due at the National Bank by 31-07-2026. Nothing is on record, 88 days later.
NBB · 10 filingsPosition against the passed deadline
31-12-2025 year end31-07-2026 deadline27-10-2026 today
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2024 was due by 31-07-2025 and was filed on 30-06-2025, 31 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
not filed
2024
31 days early
2023
82 days late
2022
31 days late
2021
29 days late
2020
67 days early
2019
157 days early
← before the deadline
after the deadline →
tick = median of all Belgian filings
This company filed its last 6 accounts on average 19 days before the deadline; the Belgian median for financial year 2024 is 4 days before the deadline, and 38% of all filings were late.
Searched, nothing found (1)
- Permanent representative: François MOISSONGazette deed
- Annual accounts filedfinancial year 2024 · abbreviated…
- Reappointment: Excelya Netherlands (director)Capital conversion · Amendment of…
Key points
By topic
Board & ownership
- Board
- 1 member
- Excelya NetherlandsDirector
Timeline
- Events
- 16
- Since
- 2016
- 21-10-2024Annual accounts filed
- 31-08-2023Annual accounts filed
- 29-08-2022Annual accounts filed
Company details
- Sites
- 1
- Legal form
- Private limited company
- Founded
- 16-10-2014
- Year ends
- 31-12
- Peppol
- Reachable for e-invoices
Articles of association
- Provisions read
- 11
- Purpose
- “Het verrichten van onderzoek op medisch gebied, in het bijzonder op het gebied van het…” (deed in Dutch)
Key facts about VASCULAR RESEARCH NETWORK BVBA
- What is the company number of VASCULAR RESEARCH NETWORK BVBA?
- 0564.780.124. In Belgium the VAT number is the company number with BE in front: BE 0564.780.124.
- Where is VASCULAR RESEARCH NETWORK BVBA based?
- The registered office is at Grauwmeer 1, 3001 Leuven.Company details
- What is the legal form of VASCULAR RESEARCH NETWORK BVBA?
- Private limited company (BV).
- When was VASCULAR RESEARCH NETWORK BVBA founded?
- On 16-10-2014.
- Is VASCULAR RESEARCH NETWORK BVBA still active?
- Yes, VASCULAR RESEARCH NETWORK BVBA is an active enterprise in the KBO register.
- What is the turnover of VASCULAR RESEARCH NETWORK BVBA?
- Not stated in the processed annual accounts. The abridged format for small companies does not require turnover.Financials
- Is VASCULAR RESEARCH NETWORK BVBA profitable?
- In financial year 2024, VASCULAR RESEARCH NETWORK BVBA made a loss of €9,572.
- Where can I find the annual accounts of VASCULAR RESEARCH NETWORK BVBA?
- VASCULAR RESEARCH NETWORK BVBA filed 10 annual accounts with the National Bank of Belgium, the latest for financial year 2024.
Go further with this company
How much credit can you give this customer, and on what payment terms?Credit check What should you check before you do business with this company?Supplier due diligence Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check How does this company compare with its sector?Sector benchmark What changed in the latest annual accounts?What changed
Your own company? See how customers, suppliers and banks see it and what to improve first.
Investigating this company? Keep it with today's facts in a case file.